Placeholder Banner

BIO's 2021 Special 301 Submission

January 29, 2021

Section 182 of the Trade Act of 1974, known as the “Special 301” provisions, requires the United States Trade Representative to identify countries that deny adequate and effective intellectual property protections or fair and equitable market access to U.S. persons who rely on IP protection. As part of the 2021 Special 301 Review process conducted by USTR, Justin Pine, J.D., Senior Director of International Affairs, prepared BIO’s formal submission to USTR and the interagency Special 301 subcommittee highlighting the IP issues facing our members in key markets around the world.

In addition to addressing systemic IP challenges abroad, BIO’s 2021 Special 301 Review Submission highlights how IP is critical to supporting BIO’s Vision, Mission, and Purpose as an enabler of biotech innovation. This year’s submission also illustrates the critical role of IP as a tool to defeat COVID-19 and as a driver of economic growth and recovery in the post-pandemic world.

 

Download Full Comments Below
BIO_2021%20Special%20301_Review_Comment.pdf
Discover More
Chairman Wyden, Ranking Member Crapo, Members of the Committee, my name is Dr. Michelle McMurry-Heath. I am the President and CEO of the Biotechnology Innovation Organization (BIO). I am honored to testify before you for today’s hearing,…
Thank you for prioritizing agricultural innovation in your recent dialogues with international counterparts. As you seek to position agriculture as a solution to domestic and global climate and sustainability challenges, the United States must…
The Biotechnology Innovation Organization (BIO) submitted the below comments to the National Institute of Standards and Technology on proposed revisions to regulations that would further the Return on Investment (ROI) Initiative for Unleashing…